Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis.
Hamimed M, Leblond P, Dumont A, Gattacceca F, Tresch-Bruneel E, Probst A, Chastagner P, Pagnier A, De Carli E, Entz-Werlé N, Grill J, Aerts I, Frappaz D, Bertozzi-Salamon AI, Solas C, André N, Ciccolini J. Hamimed M, et al. Cancer Chemother Pharmacol. 2022 Jul;90(1):29-44. doi: 10.1007/s00280-022-04446-y. Epub 2022 Jun 25. Cancer Chemother Pharmacol. 2022. PMID: 35751658 Clinical Trial.
MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors.
Vicier C, Isambert N, Cropet C, Hamimed M, Osanno L, Legrand F, de La Motte Rouge T, Ciccolini J, Gonçalves A. Vicier C, et al. Among authors: hamimed m. ESMO Open. 2022 Dec;7(6):100646. doi: 10.1016/j.esmoop.2022.100646. Epub 2022 Dec 13. ESMO Open. 2022. PMID: 36521418 Free PMC article. Clinical Trial.
Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low-grade glioma.
Hamimed M, Gattacceca F, André N, Tresch-Bruneel E, Probst A, Chastagner P, Pagnier A, De Carli E, Entz-Werlé N, Grill J, Aerts I, Frappaz D, Bertozzi-Salamon AI, Solas C, Leblond P. Hamimed M, et al. Br J Clin Pharmacol. 2022 May;88(5):2096-2117. doi: 10.1111/bcp.15131. Epub 2021 Dec 13. Br J Clin Pharmacol. 2022. PMID: 34709655 Free article. Clinical Trial.
DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.
Le TK, Cherif C, Omabe K, Paris C, Lannes F, Audebert S, Baudelet E, Hamimed M, Barbolosi D, Finetti P, Bastide C, Fazli L, Gleave M, Bertucci F, Taïeb D, Rocchi P. Le TK, et al. Among authors: hamimed m. Mol Ther. 2023 Feb 1;31(2):471-486. doi: 10.1016/j.ymthe.2022.08.005. Epub 2022 Aug 13. Mol Ther. 2023. PMID: 35965411 Free PMC article.
12 results